{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:07:47Z","timestamp":1793372867099,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T00:00:00Z","timestamp":1232323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> Hirsutism is most often caused by polycystic ovary syndrome (PCOS). PCOS patients are characterized by insulin resistance, abdominal obesity and low\u2010grade inflammation. Insulin sensitizing treatment reduces the inflammatory state, but the effect on serum levels of migration inhibitor factor (MIF), monocyte chemoattractant protein (MCP)\u20101 and macrophage inflammatory protein (MIP)\u20101\u03b1 have not been evaluated before in PCOS.<\/jats:p><jats:p><jats:bold>Research design and methods\u2002<\/jats:bold> Plasma chemokine levels (MCP\u20101, MIP\u20101\u03b1 and MIF) were measured in two study designs. (i) 51 hirsute patients and 63 matched controls and (ii) 30 PCOS patients before and after randomized treatment with 30\u00a0mg pioglitazone\/placebo for 16\u00a0weeks. Clinical evaluations and whole body DXA\u2010scans were performed in all participants.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Hirsute patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a051) had significantly increased MCP\u20101 [121 (15\u2013950) <jats:italic>vs.<\/jats:italic> 81 (18\u2013365) pg\/ml; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b705] and MIP\u20101\u03b1[179 (8\u20134202) <jats:italic>vs.<\/jats:italic> 103 (4\u20131598) pg\/ml; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b705] than controls of matched body composition [geometric mean (\u20132SD to +2SD)]. In PCOS (<jats:italic>n<\/jats:italic>\u00a0=\u00a030), MCP\u20101, MIP\u20101\u03b1 and MIF correlated positively with central fat mass. A BMI independent positive association was found between MIF and free testosterone (<jats:italic>r<\/jats:italic>\u00a0=\u00a00\u00b749, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b701) in PCOS. Pioglitazone treatment significantly improved insulin sensitivity without affecting testosterone, body composition, MCP\u20101, MIP\u20101\u03b1 and MIF levels.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Chemokine levels were significantly increased and showed close associations with measures of adiposity in PCOS patients, but were unchanged during insulin sensitizing treatment with pioglitazone. Our data suggests a fat mass independent association between testosterone and MIF levels in PCOS and the effect of anti\u2010androgen treatment on chemokine levels needs to be examined.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2009.03523.x","type":"journal-article","created":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T10:16:15Z","timestamp":1232360175000},"page":"652-658","source":"Crossref","is-referenced-by-count":75,"title":["Plasma monocyte chemoattractant protein\u20101 (MCP\u20101) and macrophage inflammatory protein\u20101\u03b1 are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment"],"prefix":"10.1111","volume":"71","author":[{"given":"Dorte","family":"Glintborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Richelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens M.","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001703-199706000-00010"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853899009147250"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07252-2"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.06.040"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031122"},{"key":"e_1_2_6_7_2","first-page":"19","volume":"81","author":"Revised 2003 consensus on diagnostic criteria and long\u2010term health risks related to polycystic ovary syndrome","year":"2004","journal-title":"Fertility and Sterility"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1549"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(95)00250-U"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.6.1255"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05488"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0436"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1228-z"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2006.04.008"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319246"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1696"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2277"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802942"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802839"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0156"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3281338546"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0800-3"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03015.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02207"},{"key":"e_1_2_6_25_2","first-page":"721","article-title":"[Association of monocyte chemoattractant protein\u20101 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases]","volume":"87","author":"Hu W.H.","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_6_26_2","first-page":"487","article-title":"[Monocyte chemoattractant protein\u20101 and its correlation with lipoprotein inpolycystic ovary syndrome]","volume":"38","author":"Hu W.H.","year":"2006","journal-title":"Beijing Da Xue Xue Bao. Yi Xue Ban"},{"key":"e_1_2_6_27_2","first-page":"CD003053","article-title":"Insulin\u2010sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d\u2010chiro\u2010inositol) for polycystic ovary syndrome","volume":"3","author":"Lord J.M.","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.3.797"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.6.8567"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032103"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02280.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0615"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.12.067"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp033496"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1985.tb01096.x"},{"key":"e_1_2_6_36_2","first-page":"199","volume-title":"Practical Statistics for Medical Research","author":"Altman D.G. (1991)"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.02.06.dc05-1474"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1811"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.364690000.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.11.022"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.019"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.05.045"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1988"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.03.037"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021688"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031281"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200207000-00008"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei072"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.03.010"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1133870100"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.578"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2009.03523.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2009.03523.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:26:57Z","timestamp":1697380017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2009.03523.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2265.2009.03523.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03523.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,5]]}}}